Ticker Details
Akebia Therapeutics, Inc. Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology.
IPO Date:	March 24, 2018
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$380.93M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.14 | 3.88%
Avg Daily Range (30 D):	$0.03 | 2.87%
Avg Daily Range (90 D):	$0.04 | 2.91%

Institutional Daily Volume
Avg Daily Volume:	2.85M
Avg Daily Volume (30 D):	4.57M
Avg Daily Volume (90 D):	3.65M

Trade Size
Avg Trade Size (Sh.):	311
Avg Trade Size (Sh.) (30 D):	196
Avg Trade Size (Sh.) (90 D):	249

Institutional Trades
Total Institutional Trades:	1,040
Avg Institutional Trade:	$1.64M
Avg Institutional Trade (30 D):	$4.44M
Avg Institutional Trade (90 D):	$2.78M
Avg Institutional Trade Volume:	.5M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.57M
Avg Closing Trade (30 D):	$4.17M
Avg Closing Trade (90 D):	$2.81M
Avg Closing Volume:	497.21K

News

Jun 23, 2026 @ 5:00 PM Acute Kidney Injury Clinical Trial Pipeline Appear... Source: Delveinsight

Feb 19, 2026 @ 1:00 PM Akebia Therapeutics to Report Fourth Quarter and F... Source: Na

Feb 4, 2026 @ 1:00 PM Akebia Therapeutics to Present at the Guggenheim E... Source: Not Specified

Dec 1, 2025 @ 2:43 PM Why Is Small-Cap Q32 Bio Stock Soaring On Monday? Source: Vandana Singh

Nov 6, 2025 @ 11:30 PM Vafseo® (vadadustat) Dialysis Dependent Patient... Source: Akebia Therapeutics

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-.08	$-.03	$-.05
Diluted EPS	$-.08	$-.03	$-.05
Revenue	$232.4M	$53.54M	$57.62M
Gross Profit	$188.28M	$41.25M	$45.09M
Net Income / Loss	$-20.51M	$-9.05M	$-12.24M
Operating Income / Loss	$5.29M	$-4.7M	$-8.55M
Cost of Revenue	$44.13M	$12.29M	$12.54M
Net Cash Flow	$49.29M	$-22.2M	$18.4M
PE Ratio